Druggability and Immunogenicity Assessment

Druggability and Immunogenicity Assessment Overview

With the advent of the era of precision medicine, monoclonal antibody drugs have become a hotspot in biological drug treatment due to their high specificity and effectiveness. As the types of monoclonal antibody drugs increase and their applications widen, related immunogenicity issues gradually emerge. For patients, immunogenicity affects the safety and effectiveness of drugs, and even brings fatal new diseases to patients due to ADA and endogenous protein cross-reactivity; for enterprises, the risk of research and development greatly increases, and if ADA problems are discovered in the late stage of clinical development, it will result in heavy losses; for drug regulatory departments, immunogenicity has also become a top priority, and all biological drugs must have an immunogenicity evaluation before they go on the market to ensure the safety and effectiveness of the drugs.With the advent of the era of precision medicine, monoclonal antibody drugs have become a hotspot in biological drug treatment due to their high specificity and effectiveness. As the types of monoclonal antibody drugs increase and their applications widen, related immunogenicity issues gradually emerge. For patients, immunogenicity affects the safety and effectiveness of drugs, and even brings fatal new diseases to patients due to ADA and endogenous protein cross-reactivity; for enterprises, the risk of research and development greatly increases, and if ADA problems are discovered in the late stage of clinical development, it will result in heavy losses; for drug regulatory departments, immunogenicity has also become a top priority, and all biological drugs must have an immunogenicity evaluation before they go on the market to ensure the safety and effectiveness of the drugs.

At present, although chimeric antibodies, humanized antibodies and fully human monoclonal antibodies have been developed in order to reduce immunogenicity, humanization has not completely eliminated ADA. Even the CDR region of humanized antibodies still has strong immunogenicity and produces unique type antibodies. We have developed an algorithm to predict antibody immunogenicity, which predicts whether the antibody peptide sequence is associated with human MHC2, whether the MHC2-peptide complex binds to TCR, whether the antibody peptide is associated with human B cells, etc., to judge whether the antibody has a risk of immunogenicity. If there is a certain risk of immunogenicity, we can also remove the immunogenicity of the antibody by designing point mutations at specific sites that cause immunogenicity. The specific process is as follows:

All Antibody Discovery Services

Hybridoma technology is the bedrock of antibody discovery, merging immunized cells to generate monoclonal antibodies. This ensures consistency, high specificity, and high yield for therapeutic and diagnostic applications.

Single B cell screening represents a breakthrough in antibody discovery. Using state-of-the-art technology to isolate, sequence, and analyze individual B cells, ensuring precise identification of specific antibodies for novel treatments.

Utilizing advanced biotechnology, our engineered bispecific antibodies bind two distinct targets. This innovation has the potential to revolutionize therapeutic strategies, heightening specificity, expanding treatment options, and paving the way for future medical advancements.

Taking advantage of camelid-derived nanobodies, we present a distinct antibody structure providing exceptional therapeutic versatility. This innovation leads to innovative approaches to treatments and diagnostics and broadens the modern medical solutions.
In silico developability assessment, transforming biomedicine by providing groundbreaking approaches to predicting antibody developability. Leveraging advanced computational insights, streamline research processes, enhance therapeutic product robustness, and accelerate innovative drug discovery.
With our profound expertise, we optimize antibodies for human compatibility, boosting therapeutic outcomes. Reducing adverse reactions, we lay the groundwork for innovative, patient-focused personalized medicine, customized for each individual.
Our comprehensive assessment of drug potential and immune responses guarantees therapeutic safety and efficacy. This rigorous process is vital in bridging the transition from lab research to successful clinical stage implementation.
Using antibodies with high specificity, we guarantee precise binding targets for CAR-T cells and biologics. This meticulous approach is foundational to therapeutic success and patient outcomes. Promoting next-generation healthcare solutions.
Targeting G-protein coupled receptors, we access an expansive therapeutic domain. Concentrating on these essential proteins, we not only enhance drug efficacy but also pioneer breakthroughs, broadening horizons in modern drug development.
Nanobodies, featuring high affinity and stability, revolutionize therapeutic approaches. Their unique properties make them invaluable, especially in the areas of targeted drug delivery, advanced diagnostics, and innovative disease intervention strategies.
KYINNO sets the standard, prioritizing high-quality antibody production. We emphasize unmatched consistency, purity, and reliability, setting industry guidelines, fostering trust, and accelerating groundbreaking drug discovery and innovative research endeavors.
Bispecific antibodies from KY-CLC bind two distinct antigens, offering advanced therapeutic avenues, enhancing drug delivery, and increasing the potential for successful patient outcomes.
Nanobodies, known for their small molecular weight, high affinity, stability, permeability, and cost-effectiveness, have demonstrated tremendous potential in disease …